Author

Tays Hernández-García

Observed names: Tays Hernandez-Garcia, Tays Hernández-Garcia

Institution: Center of Molecular Immunology (Cuba)

Observed institution: Center of Molecular Immunology (Cuba)

ORCID: 0000-0001-8414-0040

Observed ORCID: 0000-0001-8414-0040

OpenAlex ID: A5084915381

A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial

2021 · Arturo Chang-Monteagudo, Rolando Ochoa-Azze, et al. · The Lancet Regional Health - Americas · 51

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials

2022 · María Eugenia-Toledo-Romaní, Leslyhana Verdecia-Sánchez, et al. · Vaccine · 38

A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity

2022 · Sonia Pérez-Rodríguez, Meiby de la Caridad Rodríguez-González, et al. · Vaccine · 37

Screening and selection strategy for the establishment of biosimilar to trastuzumab-expressing CHO-K1 cell lines

2021 · Thailin Lao-Gonzalez, Alexi Bueno-Soler, et al. · AMB Express · 34

Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children

2022 · Rinaldo Puga-Gómez, Yariset Ricardo-Delgado, et al. · International Journal of Infectious Diseases · 33

Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults

2022 · María Eugenia Toledo-Romani, Mayra García-Carmenate, et al. · Med · 31

Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial

2022 · Rolando Ochoa-Azze, Arturo Chang-Monteagudo, et al. · The Lancet Respiratory Medicine · 29

Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial

2022 · María Eugenia Toledo-Romani, Mayra García-Carmenate, et al. · medRxiv · 5

Safety and durability of the immune response after vaccination with the heterologous schedule of anti-COVID-19 vaccines SOBERANA®02 and SOBERANA® Plus in children 3–18 years old

2024 · Dagmar García-Rivera, Rinaldo Puga-Gómez, et al. · Vaccine X · 2

Safety and Cross-Neutralizing Immunity Against SARS-CoV-2 Omicron Sub-Variant After a Booster Dose with SOBERANA® Plus in Children and Adolescents

2025 · Dagmar García-Rivera, Meiby Rodríguez-González, et al. · Vaccines · 1

Safety and Immunogenicity of Anti-SARS-CoV-2 Conjugate Vaccine SOBERANA 02: Phase IIb Clinical Trial

2022 · Maria Eugenia-Toledo-Romani, Mayra García Carmenate, et al. · SSRN Electronic Journal

Works count: 11

Citation count: 261

H-index: 7

I10-index: 7